This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC
by Zacks Equity Research
The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.
Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold
by Zacks Equity Research
Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold
Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY
by Kinjel Shah
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.
Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY
by Zacks Equity Research
The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY
GNC Holdings' (GNC) Q1 Earnings and Sales Miss Estimates
by Zacks Equity Research
All the operating segments of GNC Holdings (GNC) register significant year-over-year sales decline in Q1 on coronavirus-led business disruption.
AMN Healthcare (AMN) Q1 Earnings In Line With Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gained from core operating segments in Q1.
Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.
Fight Off the Coronavirus Blues With 5 Low-Beta Stocks
by Nilanjan Banerjee
It is an ideal time to invest in low-beta stocks since they might provide a shield against coronavirus-induced market volatility.
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs
by Sweta Jaiswal, FRM
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines
by Zacks Equity Research
Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.
HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.
Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks
by Kinjel Shah
Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.
Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.
National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results benefit from strength in Cardio & Vascular sub-segment and margin expansion.
ESG Stocks Remain Resilient to Virus Slump: 5 Top Picks
by Zacks Equity Research
ESG stocks bear lesser financial risk due to their focus on environment, employees and supply chain. Investment in these companies can return well.
Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.
Insulet (PODD) Q1 Earnings Lag Estimates, Margins Decline
by Zacks Equity Research
Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.
Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.
Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from strong segmental performance.
LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
LHC Group (LHCG) continues to gain from home health services and hospice admissions, which improved year over year in Q1.
Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Radius (RDUS) reports wider-than-expected loss but beats sales estimates in the first quarter. The company lowers guidance for 2020.
Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY
by Kinjel Shah
Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.